Icon (ICLR) Receiving Somewhat Positive Press Coverage, Study Shows
Headlines about Icon (NASDAQ:ICLR) have trended somewhat positive on Saturday, according to Accern. Accern identifies positive and negative press coverage by analyzing more than 20 million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Icon earned a news impact score of 0.15 on Accern’s scale. Accern also gave news articles about the medical research company an impact score of 44.4702549408897 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the next few days.
These are some of the media stories that may have effected Accern’s scoring:
- ICON Wins Best Contract Research Organisation at the Annual Scrip … – Markets Insider (markets.businessinsider.com)
- ICON plc – Value Analysis (NASDAQ:ICLR) : December 1, 2017 (finance.yahoo.com)
- ICON Wins Best Contract Research Organisation at the Annual Scrip … – Business Wire (press release) (businesswire.com)
- Earnings Growth Metrics Drive Icon (ICLR) to Strong Buy – Investorplace.com (investorplace.com)
A number of brokerages have recently issued reports on ICLR. Zacks Investment Research lowered Icon from a “buy” rating to a “hold” rating in a research report on Wednesday, November 1st. ValuEngine downgraded Icon from a “buy” rating to a “hold” rating in a research note on Monday, October 2nd. Jefferies Group increased their price objective on Icon from $122.00 to $132.00 and gave the company a “buy” rating in a research note on Monday, October 9th. Robert W. Baird reissued a “buy” rating and issued a $123.00 price objective on shares of Icon in a research note on Thursday, October 12th. Finally, Barclays increased their price objective on Icon from $108.00 to $120.00 and gave the company an “equal weight” rating in a research note on Friday, October 27th. Four analysts have rated the stock with a hold rating, seven have given a buy rating and two have assigned a strong buy rating to the company’s stock. Icon currently has an average rating of “Buy” and an average target price of $121.00.
Icon (NASDAQ:ICLR) last posted its quarterly earnings data on Thursday, October 26th. The medical research company reported $1.35 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $1.32 by $0.03. Icon had a return on equity of 28.42% and a net margin of 16.37%. The firm had revenue of $440.30 million during the quarter, compared to the consensus estimate of $438.09 million. During the same period in the prior year, the company earned $1.19 EPS. The firm’s revenue was up 4.8% compared to the same quarter last year. equities analysts predict that Icon will post 5.36 earnings per share for the current year.
TRADEMARK VIOLATION WARNING: “Icon (ICLR) Receiving Somewhat Positive Press Coverage, Study Shows” was published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this piece on another site, it was illegally copied and republished in violation of U.S. and international trademark & copyright legislation. The correct version of this piece can be read at https://www.thecerbatgem.com/2017/12/02/icon-iclr-receiving-somewhat-positive-press-coverage-study-shows.html.
Icon Company Profile
ICON public limited company is a contract research organization (CRO), which is engaged in providing outsourced development services to the pharmaceutical, biotechnology and medical device industries. The Company is engaged in the strategic development, management and analysis of programs that support the various stages of the clinical development process, from compound selection to Phase I-IV clinical studies.
Receive News & Stock Ratings for Icon Plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Icon Plc and related stocks with our FREE daily email newsletter.